Sensorion has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The submission is a preliminary step in the company's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of ADSs, and the listing of such ADSs on a U.S. national exchange.
Sensorion is a clinical-stage biotech company, which specializes in the development of therapies to restore, treat, and prevent hearing loss disorders. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: [email protected]
Business News
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.